A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection
Dropulic L, Oestreich M, Pietz H, Laing K, Hunsberger S, Lumbard K, Garabedian D, Turk S, Chen A, Hornung R, Seshadri C, Smith M, Hosken N, Phogat S, Chang L, Koelle D, Wang K, Cohen J. A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection. The Journal Of Infectious Diseases 2019, 220: 990-1000. PMID: 31058977, PMCID: PMC6688060, DOI: 10.1093/infdis/jiz225.Peer-Reviewed Original ResearchConceptsHerpes simplex virus 2T cell responsesCD4+ T cell responsesHerpes simplex virusDose of vaccinePlacebo recipientsDouble-blindCD8+ T cell responsesReplication-defective herpes simplex virusSolicited injection site reactionsHerpes simplex virus infectionThird dose of vaccineSystemic reactions to vaccinationPlacebo-controlled trialPhase 1 studyInjection site reactionsNeutralizing antibody titersPlacebo-ControlledGenital herpesThird doseSite reactionsSimplex virusVaccine recipientsNeutralizing antibodiesReactions to vaccination
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply